[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Views 418
Citations 0
Comment & Response
October 26, 2018

Failure to Accurately Disclose Conflicts of Interest in Articles Published in JAMA Oncology

Author Affiliations
  • 1Vall d’Hebron Institute of Oncology (VHIO), Cellex Center, Barcelona, Spain
JAMA Oncol. Published online October 26, 2018. doi:10.1001/jamaoncol.2018.5674

To the Editor I write to take full responsibility for failing to report appropriate conflicts of interest disclosures in articles published in JAMA Oncology and the JAMA Network journals between 2015 and 2018, including 5 articles published in JAMA Oncology.1-5 In 3 of these article I had reported receiving personal fees from Roche, and in 2 articles I had reported nothing to disclose. In the interest of full disclosure, I now report the following financial interests and activities that I had been involved from 2013 to the present time, regardless of potential relevance:

“Dr Baselga reports nonfinancial support and reasonable reimbursement for travel from Roche/Genentech; receiving fees from and stock ownership in the following companies: Aura Biosciences (including serving on the board of directors from 2013-2017), Infinity Pharmaceuticals (including serving on the board of directors from 2013-2017), PMV Pharma Biotechnologies (including serving on the scientific advisory board from 2014-present), Juno Therapeutics (acquired by Celgene) (including serving on the scientific advisory board from 2014-2017), Grail (including serving as member or chair of the scientific advisory board from 2016-2018), Varian Medical Systems (including serving on the board of directors from 2017-2018), Bristol-Myers Squibb (including serving on the board of directors from March to September 2018), Seragon (acquired by Roche) (including serving on the scientific advisory board of directors from 2013-2014); stock ownership in ApoGen Biotechnologies (including serving on the scientific advisory board from 2014-present), and Foghorn Therapeutics (including serving on the board from 2017-present); serving as cofounder, receiving fees from, and stock ownership in Tango (formerly Synthetic Lethal) from 2016-present and Northern Biologics (formerly Mosaic Biomedicals) (including serving on the scientific advisory board from 2013-present); receiving consulting and travel fees from Novartis and Eli Lilly; serving as cofounder of Venthera; and serving as investigator on a patent licensed to Memorial Sloan Kettering for use of phosphoinositide 3-kinase inhibitors for treatment of vascular malformations and serving as investigator for patents pending assignment to Memorial Sloan Kettering for combination therapy using PDK1 and PI3K inhibitors and inhibition of KMT2D for the treatment of breast cancer.”

I hope that this complete list is helpful to readers and editors as they evaluate the underlying research—of which I remain proud to have been affiliated. I have requested that the articles be corrected online6 to provide this complete disclosure and a link to this Letter.

Back to top
Article Information

Corresponding Author: José Baselga, MD, PhD, Vall d’Hebron Institute of Oncology (VHIO), Cellex Center, C/ Natzaret, 115-117, 08035 Barcelona, Spain (jbaselga@vhio.net).

Published Online: October 26, 2018. doi:10.1001/jamaoncol.2018.5674

Conflict of Interest Disclosure: Dr Baselga reports nonfinancial support and reasonable reimbursement for travel from Roche/Genentech; receiving fees from and stock ownership in the following companies: Aura Biosciences (including serving on the board of directors from 2013-2017), Infinity Pharmaceuticals (including serving on the board of directors from 2013-2017), PMV Pharma Biotechnologies (including serving on the scientific advisory board from 2014-present), Juno Therapeutics (acquired by Celgene) (including serving on the scientific advisory board from 2014-2017), Grail (including serving as member or chair of the scientific advisory board from 2016-2018), Varian Medical Systems (including serving on the board of directors from 2017-2018), Bristol Myers Squibb (including serving on the board of directors from March to September 2018), Seragon (acquired by Roche) (including serving on the scientific advisory board from 2013-2014); stock ownership in ApoGen Biotechnologies (including serving on the scientific advisory board from 2014-present), and Foghorn Therapeutics (including serving on the board from 2017-present); serving as cofounder, receiving fees from, and stock ownership in Tango (formerly Synthetic Lethal) from 2016-present and Northern Biologics (formerly Mosaic Biomedicals) (including serving on the scientific advisory board from 2013-present); receiving consulting and travel fees from Novartis and Eli Lilly; serving as cofounder of Venthera; and serving as investigator on a patent licensed to Memorial Sloan Kettering for use of phosphoinositide 3-kinase inhibitors for treatment of vascular malformations and serving as investigator for patents pending assignment to Memorial Sloan Kettering for combination therapy using PDK1 and PI3K inhibitors and inhibition of KMT2D for the treatment of breast cancer.

References
1.
Ptashkin  RN, Mandelker  DL, Coombs  CC,  et al.  Prevalence of clonal hematopoiesis mutations in tumor-only clinical genomic profiling of solid tumors  [published online June 5, 2018].  JAMA Oncol. doi:10.1001/jamaoncol.2018.2297PubMedGoogle Scholar
2.
Diamond  EL, Subbiah  V, Lockhart  AC,  et al.  Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study.  JAMA Oncol. 2018;4(3):384-388. doi:10.1001/jamaoncol.2017.5029PubMedGoogle ScholarCrossref
3.
Fumagalli  D, Venet  D, Ignatiadis  M,  et al.  RNA sequencing to predict response to neoadjuvant anti-HER2 therapy: a secondary analysis of the NeoALTTO randomized clinical trial.  JAMA Oncol. 2016;3(2):227-234. doi:10.1001/jamaoncol.2016.3824PubMedGoogle ScholarCrossref
4.
Chandarlapaty  S, Chen  D, He  W,  et al.  Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 Clinical Trial.  JAMA Oncol. 2016;2(10):1310-1315. doi:10.1001/jamaoncol.2016.1279PubMedGoogle ScholarCrossref
5.
Salgado  R, Denkert  C, Campbell  C,  et al.  Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial.  JAMA Oncol. 2015;1(4):448-454. doi:10.1001/jamaoncol.2015.0830PubMedGoogle ScholarCrossref
6.
 Missing conflict of interest disclosure  [published online October 26, 2018].  JAMA Oncol. doi:10.1001/jamaoncol.2018.5678Google Scholar
×